National Institutes of Health Director Jay Bhattacharya, M.D., Ph.D., on Monday named John H. Powers III, M.D., to lead the NIH’s National Institute of Allergy and Infectious Diseases, or NIAID.
NIH said Dr. Powers will lead work that affects research across infectious, immunologic and allergic diseases, including support for studies at universities, scientific institutions and small businesses in the United States and abroad. The agency said NIAID also helps enable responses to new and recurring public health threats.
As director, Dr. Powers will put in place NIAID’s research agenda, which NIH said was recently set out in a new strategic plan, and manage the institute’s $6.56 billion annual budget. NIH said NIAID’s laboratories include the Vaccine Research Center on the NIH campus in Bethesda, Md., and the Rocky Mountain Laboratories in Hamilton, Mont.
NIH said he is serving as NIAID’s acting director and principal deputy director, and also practices as an infectious diseases attending at the NIH Clinical Center. Bhattacharya said Dr. Powers “will bring a focus on rigor, transparency, and research outcomes to leading the institute into the future.”
NIH said Dr. Powers has more than three decades of experience in clinical medicine, infectious diseases research, regulatory science, clinical trial design and outcomes research. He has authored more than 150 peer‑reviewed papers. According to NIH, his work has aimed to ensure that trials measure results that matter to patients, such as survival, function, symptoms and quality of life. NIH said he helped develop patient‑reported outcome tools for influenza and chronic obstructive pulmonary disease and contributed to international standards for clinical outcome assessments and surrogate endpoints.
According to NIH, Dr. Powers has been an infectious diseases attending at NIAID since 1999 and, over the last two decades, has led collaborative research at Leidos Biomedical Research in support of the institute. He received NIH Director’s Awards for work during the H1N1 influenza response and the COVID‑19 pandemic, NIH said.
Before joining NIH, Dr. Powers worked at the U.S. Food and Drug Administration from 1998 to 2006, serving first as a medical officer and later as the lead medical officer on antimicrobial drug development and resistance efforts in the Office of Antimicrobial Products, NIH said. He also took part in working groups with the Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the Foundation for the NIH, and testified before the U.S. House Committee on Energy and Commerce on antibiotic resistance and drug development.
According to NIH, Dr. Powers holds a clinical medicine professorship at the George Washington University School of Medicine and is an affiliate professor at the University of Maryland School of Pharmacy. NIH said he has taught and mentored medical students, residents and fellows for more than 30 years and serves as a research editor at The BMJ.
